Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels - Wikidata - wikimedia - TriplyDB

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

http://www.wikidata.org/entity/Q28301776

about

Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels.Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality Individualizing endpoints in randomized clinical trials to better inform individual patient care: the TARGET proposal Detrimental cross-talk between sepsis and acute kidney injury: new pathogenic mechanisms, early biomarkers and targeted therapies Balancing Innate Immunity and Inflammatory State via Modulation of Neutrophil Function: A Novel Strategy to Fight Sepsis Biomarkers of sepsis Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets Using data-driven rules to predict mortality in severe community acquired pneumonia.Intravenous immunoglobulin for treating sepsis and septic shock.Release of data from an ongoing randomized clinical trial for sample size adjustment or planning.Streptococcus pneumoniae and Pseudomonas aeruginosa pneumonia induce distinct host responses CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs.Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock.The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.Systems engineering medicine: engineering the inflammation response to infectious and traumatic challenges.Hypervolemia induces and potentiates lung damage after recruitment maneuver in a model of sepsis-induced acute lung injury.Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels.Abandon the mouse research ship? Not just yet!Red blood cell distribution width during the first week is associated with severity and mortality in septic patients.Have we overestimated the benefit of human(ized) antibodies?New approaches to sepsis: molecular diagnostics and biomarkers.Inhibiting TNF-α signaling does not attenuate induction of endotoxin tolerance The effect of progesterone on systemic inflammation and oxidative stress in the rat model of sepsis.Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis.Activation of common antiviral pathways can potentiate inflammatory responses to septic shock.Chronic sepsis mortality characterized by an individualized inflammatory response Ceramide kinase regulates the production of tumor necrosis factor α (TNFα) via inhibition of TNFα-converting enzyme.Biomarkers of necrotising soft tissue infections: aspects of the innate immune response and effects of hyperbaric oxygenation-the protocol of the prospective cohort BIONEC study Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis?Prevention of sepsis in children: a new paradigm for public policy.Decoy Receptor 3 Improves Survival in Experimental Sepsis by Suppressing the Inflammatory Response and Lymphocyte Apoptosis.Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study.The pediatric sepsis biomarker risk model: potential implications for sepsis therapy and biology.Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.Sepsis chronically in MARS: systemic cytokine responses are always mixed regardless of the outcome, magnitude, or phase of sepsis.What is new in cytokine research related to trauma/critical care.The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death

P2860

Q21092899-272EA130-8A6F-432B-90FE-282324B1E782 Q24198059-B773E303-5F55-4936-B375-1C08C3F4B98B Q24676668-3A46B06D-CA8F-4E2C-A6BB-DCF60FE58C0E Q26739895-586D21E4-B699-4FA2-BC7C-8741016B8EE4 Q26765788-4EA39D2B-02B0-4BC9-B0E4-ABB62D04C2A3 Q26769674-3B665804-D751-44D6-AF70-59E85DD6D6C9 Q26822575-32BD38E3-0CD3-4E5B-A12D-C7118B7EE8FF Q28077955-00233303-CFB4-42E8-AD05-2FF02F70D6E0 Q30793094-F8A9DCCA-CD3B-4F9C-AE17-4A5166C609E1 Q30820719-6A29BA29-CAED-4BB2-B395-E8D5BBE040D0 Q33275980-FDD2515A-0C33-45CB-8EEC-A5D42F3329B7 Q33551373-2EAFD4C5-9467-4269-BA1D-CEBF4E913B85 Q33694581-C799B381-A43E-456A-A883-5A3A8B83C66D Q33721339-DC8D294E-902E-416F-8F5A-6BEF229ED1C5 Q33750231-0D62048B-DE93-4909-9A4F-9B847C405386 Q33891519-65EFD27C-9420-4B88-9956-4A8F179273DB Q34027021-7709CF9F-BBDD-4123-95BD-298DD08D384B Q34049911-D817701D-41F8-4F6A-A468-1775230843C6 Q34069683-63B3FBB3-16A8-4BBA-A1F3-7A2B997DCD3F Q34083809-33C72C23-12E2-46B2-9C01-1AA49E0F0653 Q34142714-B8A308F6-BAB0-4116-A7AF-EAA38D1165C8 Q34303687-19BE769F-6892-4A86-B93A-FE5C27BAFC9E Q34655635-C5CD9C88-0415-4297-A28C-85960E92107D Q34684628-0CBDA136-8A76-4ED0-8740-6713FB6CD639 Q34726541-B67F6637-0124-4408-905E-2524A650C946 Q34726827-C1926552-75C2-47E7-A254-03A1962872DD Q34866465-D3F97726-1FDC-42F0-96DA-20D011A43326 Q34885791-F9F64BD9-DEE8-461D-8D1B-B6BF72C8F47E Q35600970-83BD7D63-2975-45EF-BEDE-5768C6C97F4A Q35604572-AED46289-040C-4F8C-9B99-0A053F0AA434 Q35604874-545E5274-22DD-44D1-B982-3876BC7FC19A Q35622257-BA7FE5E9-0653-466D-A292-20C0800B61EC Q35636062-D124F9FE-4144-481A-9D71-676B7CD135E3 Q35677311-CD1D6946-FE56-4CD1-93AD-E1F474BC1DCA Q35830749-BBB308FC-2FBE-457A-8014-D83544707992 Q36181988-B26E2C90-5DE3-4F53-AB53-6F5384A02F30 Q36310139-1030ACE7-383A-4A74-A71B-719D6BFF52B5 Q36339054-E0BE785B-6256-4C10-A7F5-C668F049E307 Q36421394-2EE020FA-231A-463C-ADBE-BC755A3B92BD Q36469613-CF9347BB-35ED-4C66-AD75-1FBD339CED9E

P2860

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

http://www.wikidata.org/entity/Q28301776

description

2004 nî lūn-bûn

@nan

2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Efficacy and safety of the mon ...... elevated interleukin-6 levels

@ast

Efficacy and safety of the mon ...... elevated interleukin-6 levels

@en

Efficacy and safety of the mon ...... elevated interleukin-6 levels

@nl

type

label

Efficacy and safety of the mon ...... elevated interleukin-6 levels

@ast

Efficacy and safety of the mon ...... elevated interleukin-6 levels

@en

Efficacy and safety of the mon ...... elevated interleukin-6 levels

@nl

prefLabel

Efficacy and safety of the mon ...... elevated interleukin-6 levels

@ast

Efficacy and safety of the mon ...... elevated interleukin-6 levels

@en

Efficacy and safety of the mon ...... elevated interleukin-6 levels

@nl

P1433

Q28301776-07302655-84EA-47B3-95EA-531F3C880C0C

P1476

Q28301776-4B708386-E6E0-45B0-ABE9-0B1CF0DA7F5E

P2093

Q28301776-03B9F999-156B-407B-AD30-1B153E58B8F0

Q28301776-17E82BD5-B23B-4540-9575-D11CC6C03828

Q28301776-1A760CCD-8392-4DA5-B8C3-265F930EF5FA

Q28301776-2965522B-7D22-4C07-895C-CABA27783AC7

Q28301776-3D8F6BA2-7F91-4C99-8115-D3D188041F07

Q28301776-4229EA7F-584B-443B-9DEC-E90B085CAFF5

Q28301776-50A7BE6A-BB60-408F-B228-4AAA7173114D

Q28301776-62BBE0F0-43A2-4917-A9C8-998228EDC068

Q28301776-7C779E49-AB27-4F4C-8300-E92DCD12F449

Q28301776-7DB93E1C-96E5-43FF-B3D2-CC1E677EEC91

P304

Q28301776-B727DF10-D33E-444A-AF4B-A8E33742FE29

P31

Q28301776-3999D3AF-8F98-49F9-88E7-6BFD73BE26A4

P3181

Q28301776-7AD4B659-DC9F-41C1-97AC-DB9814225C89

P356

Q28301776-5A876228-B6D2-4730-B42C-7FC65C03B8D0

P407

Q28301776-EBAFDA48-D912-4AD3-B92D-106E373AD93D

P433

Q28301776-F21A6A1E-8EDC-4EA5-9A65-2E59DDA9116E

P478

Q28301776-ECCD29CA-0334-4009-90EF-188955F83B32

P577

Q28301776-512BBE85-25F9-4E47-9813-DCEDCA33656E

P5875

Q28301776-FA6A300D-96F7-44CB-BF8D-E95AEC653408

P698

Q28301776-1AEC0AE4-CD2D-4086-8A88-BEA189416722

P921

Q28301776-56f1f584-bd27-48d3-9153-3219e34999ac

Q28301776-6A77ABF4-6B9D-42B5-9547-144ABA7D3AF4

Q28301776-BB48C89C-A2CB-44CE-9315-1A92136547F7

Q28301776-C525688B-B59E-4F1C-8B12-F87D412B65F7

P3181

P356

01.CCM.0000145229.59014.6C

P1433

Critical Care Medicine

P1476

Efficacy and safety of the mon ...... elevated interleukin-6 levels

@en

P2093

Christopher Doig

http://www.w3.org/2001/XMLSchema#string

David H Johnson

http://www.w3.org/2001/XMLSchema#string

Edward A Panacek

http://www.w3.org/2001/XMLSchema#string

Gregory Hicklin

http://www.w3.org/2001/XMLSchema#string

John C Marshall

http://www.w3.org/2001/XMLSchema#string

Leah Teoh

http://www.w3.org/2001/XMLSchema#string

Lori Van Meter

http://www.w3.org/2001/XMLSchema#string

Lothar Daum

http://www.w3.org/2001/XMLSchema#string

Mark Miller

http://www.w3.org/2001/XMLSchema#string

Martin Kaul

http://www.w3.org/2001/XMLSchema#string

P304

2173-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3795251

http://www.w3.org/2001/XMLSchema#string

P356

10.1097/01.CCM.0000145229.59014.6C

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8089981

http://www.w3.org/2001/XMLSchema#string

P698

15640628

http://www.w3.org/2001/XMLSchema#string

P921